

6/03
S. PTO

1/19




FIG. 1A

FIG. 1B

3/
S-
PTO

2/19




FIG. 1C

£0/
S. PTO

3/19




FIG. 1D

6/3 U.S. PTO

4/19




FIG. 1E

€0/
S
PTO

5/19




FIG. 2A

19/03
U.S. PTO

6/19




FIG. 2B




FIG. 2C

8/19



FIG. 3A**FIG. 3B**

FIG. 4A




FIG. 4B





FIG. 4C



10/19




Cytosol with GST-NF κ Bp65 wtNuclear with GST-NF κ Bp65 wt

FIG. 5A

30/€
S
OPIA

11/19

Cytosol IP with α -NF κ Bp65



Nuclear IP with α -NF κ Bp65





FIG. 5B


03/
S. PTO

FIG. 5C



12/19

FIG. 5D



1. S. PTO
3/03

13/19





FIG. 6A



EIG 6B

9/03
U.S. PTO

14/19




FIG. 6C




FIG. 6D

3/60
S. PTO

15/19




FIG. 7A




FIG. 7B




FIG. 7C

9/03
J.S. PTO

16/19




FIG. 8A




FIG. 8B




FIG. 8C

30/6
U.S. PTO

17/19





FIG. 9B

O I P E
JUN 09 2003
PATENT & TRADEMARK OFFICE

18/19




FIG. 10A




FIG. 10B